Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma

Abstract

We evaluated the association between the expression of myeloid antigens on neoplastic plasma cells and patient prognosis. The expression status of CD13, CD19, CD20, CD33, CD38, CD56, and CD117 was analyzed on myeloma cells from 55 newly diagnosed patients, including 36 men (65%), of median age 61 years (range: 38–78). Analyzed clinical characteristics and laboratory parameters were as follows: serum β2-microglobulin, lactate dehydrogenase, calcium, albumin, hemoglobin, serum creatinine concentrations, bone marrow histology, and cytogenetic findings. CD13+ and CD33+ were detected in 53% and 18%, respectively. Serum calcium (P = 0.049) and LDH (P = 0.018) concentrations were significantly higher and morphologic subtype of immature or plasmablastic was more frequent in CD33+ than in CD33− patients (P = 0.022). CD33 and CD13 expression demonstrate a potential prognostic impact and were associated with lower overall survival (OS; P = 0.001 and P = 0.025) in Kaplan-Meier analysis. Multivariate analysis showed that CD33 was independently prognostic of shorter progression free survival (PFS; P = 0.037) and OS (P = 0.001) with correction of clinical prognostic factors. This study showed that CD13 and CD33 expression associated with poor prognosis in patients with MM implicating the need of analysis of these markers in MM diagnosis.

Prognostic Value of CD56 Expression in Multiple Myeloma

“…In the current study, 84% of patients were CD56 positive, which is much higher than the 42% prevalence found by Boshnak and Hashem 14 . Other studies done by Pan et al 11 , Qiu et al 15 and Shim et al 16 reported a prevalence of 71%, 61% and 66%; which is not much lower than that in our study. The presence of CD56 has been related to malignancy in plasma cells, and its downregulation has been shown to be associated with high proliferation and spreading of malignant plasma cells 9 .…”

“…CD56 is a homophilic binding glycoprotein implicated in cell-cell adhesion that is involved in attaching plasma cells to the stromal structure of the bone marrow 1 . The prevalence of CD56 positivity in MM varied among studies 11,[14][15][16] . In the current study, 84% of patients were CD56 positive, which is much higher than the 42% prevalence found by Boshnak and Hashem 14 .…”

Primary malignant myelomatous pleural effusion

“…). Morphologic subtypes have been shown to be important prognostic factors, with a trend toward immaturity strongly associated with poor prognosis . Mott cells, named after the surgeon F. W. Mott, are plasma cells with spherical inclusion bodies (Fig.…”

“…The prognosis of patient with PMMPE is very poor . The morphology of the plasma cells also have a bearing on the prognosis of the patient where plasmablastic differentiation has been shown to be associated with poor prognosis . In this case report, we will discuss the incidence and presentation of PMMPE, morphology of immature plasma cells and mott cells with Russell bodies.…”

Characterization of a new human plasma cell leukemia cell line UHKT‐944

“…Indeed, this appears to be of significant importance emerging from a study where CD28‐mediated ligation of CD80/CD86 on stromal dendritic cells directly transduced a prosurvival signal to myeloma cell, protecting it against chemotherapy and growth factor withdrawal‐induced death, and induced the dendritic cells to produce the prosurvival cytokine IL‐6 . The aberrant expression of CD28 and myeloid CD33 , the presence of CD98 , and the absence of CD56 and CD117 have been shown to correlate with a poor prognosis of plasma cell‐derived malignancies. The same expression pattern (except slight expression of CD56) was found in UHKT‐944 cells, which is in agreement with rapid progress of the patient's disease.…”